- Home
- FAAS vs ELEV Comparison
FAAS vs ELEV Comparison
Compare FAAS & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAAS
- ELEV
- Stock Information
- Founded
- FAAS 2021
- ELEV 2019
- Country
- FAAS Indonesia
- ELEV United States
- Employees
- FAAS N/A
- ELEV N/A
- Industry
- FAAS
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- FAAS
- ELEV Health Care
- Exchange
- FAAS NYSE
- ELEV Nasdaq
- Market Cap
- FAAS 34.6M
- ELEV 37.6M
- IPO Year
- FAAS N/A
- ELEV 2021
- Fundamental
- Price
- FAAS $0.54
- ELEV $0.51
- Analyst Decision
- FAAS
- ELEV Buy
- Analyst Count
- FAAS 0
- ELEV 6
- Target Price
- FAAS N/A
- ELEV $7.20
- AVG Volume (30 Days)
- FAAS 304.0K
- ELEV 1.1M
- Earning Date
- FAAS 09-17-2024
- ELEV 03-06-2025
- Dividend Yield
- FAAS N/A
- ELEV N/A
- EPS Growth
- FAAS N/A
- ELEV N/A
- EPS
- FAAS N/A
- ELEV N/A
- Revenue
- FAAS $57,730,593.00
- ELEV N/A
- Revenue This Year
- FAAS N/A
- ELEV N/A
- Revenue Next Year
- FAAS N/A
- ELEV N/A
- P/E Ratio
- FAAS N/A
- ELEV N/A
- Revenue Growth
- FAAS 38.16
- ELEV N/A
- 52 Week Low
- FAAS $0.38
- ELEV $0.42
- 52 Week High
- FAAS $12.97
- ELEV $5.83
- Technical
- Relative Strength Index (RSI)
- FAAS 46.84
- ELEV 37.68
- Support Level
- FAAS $0.50
- ELEV $0.42
- Resistance Level
- FAAS $0.57
- ELEV $0.53
- Average True Range (ATR)
- FAAS 0.08
- ELEV 0.06
- MACD
- FAAS 0.00
- ELEV -0.01
- Stochastic Oscillator
- FAAS 38.81
- ELEV 31.41
About FAAS DIGIASIA CORP
DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.